Free press releases distribution network?

Agency / Source: rPeptide, LLC

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!



Alpha Synuclein-rPeptide Introduces New Proteins - Alpha Synuclein, 1-60 Alpha Synuclein, 1-95 Alpha Synuclein, 61-140 Alpha Synuclein, 96-140
Alpha Synuclein-rPeptide Introduces New Proteins

 

PRZOOM - /newswire/ - Bogart, GA, United States, 2008/05/15 - Alpha Synuclein, 1-60 Alpha Synuclein, 1-95 Alpha Synuclein, 61-140 Alpha Synuclein, 96-140.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Alpha Synuclein, 1-60
MW: 6,149 Da
Lyophilized powder. Purity > 95% by SDS-PAGE; A deletion mutant of Alpha-Synuclein (amino acids 1-60), which contains the N-terminal amphipathic domain. Alpha-Synuclein is a 14 kD (140 amino acids) acidic presynaptic protein. It is a major component of Parkinsonís disease aggregates and is implicated in the pathogenesis of Parkinsonís Disease and related neurodegenerative disorders. Alpha-Synuclein accumulates in the brains of sporadic Parkinsonís disease patients as a major component of Lewy bodies, which are intraneuronal cytoplasmic inclusions characteristic of Parkinsonís disease. Alpha-Synuclein appears to associate with other proteins that aggregate and is found in amyloid plaques and neuritic tangles in Alzheimerís disease.
References:
Conway, K.A. et. al., (2000) Biochemistry, 39: 2552
Jakes, R. et al. 1994, FEBS Letters, 345, 27
Masliah, E. et. al., 2001. Proc. Natl. Acad. Sci., USA, 98, 12245
Ueda, K., et. al. 1993. Proc. Natl. Acad. Sci., USA, 90, 11282

Alpha Synuclein, 1-95
MW: 9,391 Da
Description: Lyophilized powder. Purity > 95% by SDS-PAGE; A deletion mutant of Alpha-Synuclein (amino acids 1-95), which contains the N-terminal amphipathic domain and the NAC region. Alpha-Synuclein is a 14 kD (140 amino acids) acidic presynaptic protein. It is a major component of Parkinsonís disease aggregates and is implicated in the pathogenesis of Parkinsonís Disease and related neurodegenerative disorders. Alpha-Synuclein accumulates in the brains of sporadic Parkinsonís disease patients as a major component of Lewy bodies, which are intraneuronal cytoplasmic inclusions characteristic of Parkinsonís disease. Alpha-Synuclein appears to associate with other proteins that aggregate and is found in amyloid plaques and neuritic tangles in Alzheimerís disease.
References:
Conway, K.A. et. al., (2000) Biochemistry, 39: 2552
Jakes, R. et al. 1994, FEBS Letters, 345, 27
Masliah, E. et. al., 2001. Proc. Natl. Acad. Sci., USA, 98, 12245
Ueda, K., et. al. 1993. Proc. Natl. Acad. Sci., USA, 90, 11282

Alpha-Synuclein, 61-140

MW: 8,460 Da
Description: Lyophilized powder. Purity > 95% by SDS-PAGE; A deletion mutant of Alpha-synuclein (amino acids 61-140). Additional amino acid (Met) is attached at the N-terminus. Alpha-Synuclein is a 14 kD (140 amino acids) acidic presynaptic protein. It is a major component of Parkinsonís disease aggregates and is implicated in the pathogenesis of Parkinsonís Disease and related neurodegenerative disorders. Alpha-Synuclein accumulates in the brains of sporadic Parkinsonís disease patients as a major component of Lewy bodies, which are intraneuronal cytoplasmic inclusions characteristic of Parkinsonís disease. Alpha-Synuclein appears to associate with other proteins that aggregate and is found in amyloid plaques and neuritic tangles in Alzheimerís disease.

References:
Park, S. M. et al. (2002) Blood, 100(7) 2506
Park, S. M. et al. (2002) Biochemisty. 41, 4137
Conway, K.A. et. al., (2000) Biochemistry, 39: 2552
Jakes, R. et al. 1994, FEBS Letters, 345, 27
Masliah, E. et. al., 2001. Proc. Natl. Acad. Sci., USA, 98, 12245
Ueda, K., et. al. 1993. Proc. Natl. Acad. Sci., USA, 90, 11282

Alpha-Synuclein, 96-140

MW: 5,217 Da
Description: Lyophilized powder. Purity > 95% by SDS-PAGE; A deletion mutant of Alpha-Synuclein (amino acids 96-140). Additional amino acid (Met) is attached at the N-terminus. Alpha-Synuclein is a 14 kD (140 amino acids) acidic presynaptic protein. It is a major component of Parkinsonís disease aggregates and is implicated in the pathogenesis of Parkinsonís Disease and related neurodegenerative disorders. Alpha-Synuclein accumulates in the brains of sporadic Parkinsonís disease patients as a major component of Lewy bodies, which are intraneuronal cytoplasmic inclusions characteristic of Parkinsonís disease. Alpha-Synuclein appears to associate with other proteins that aggregate and is found in amyloid plaques and neuritic tangles in Alzheimerís disease.

References:
Park, S. M. et al. (2002) Blood, 100(7) 2506
Park, S. M. et al. (2002) Biochemisty. 41, 4137
Conway, K.A. et. al., (2000) Biochemistry, 39: 2552
Jakes, R. et al. 1994, FEBS Letters, 345, 27
Masliah, E. et. al., 2001. Proc. Natl. Acad. Sci., USA, 98, 12245
Ueda, K., et. al. 1993. Proc. Natl. Acad. Sci., USA, 90, 11282

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: rPeptide, LLC

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick PRZOOM - Press & Newswire Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Alpha Synuclein-rPeptide Introduces New Proteins

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name PRZOOM - Press & Newswire and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
|
Contact: Sanjay Bhardwaj - rPeptide.com 
+91 41 829529 sanjayb[.]rpeptide.com
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any rPeptide, LLC securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!




Read Latest Press Releases From rPeptide, LLC / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Press Releases:

U.S. FDA Approves New Indication for Ipsenís Somatulineģ Depot (lanreotide) Injection for the Treatment of Carcinoid Syndrome
Genentech Provides Update on First Lampalizumab Phase III Study for Geographic Atrophy, an Advanced Form of Age-Related Macular Degeneration
mProve Health and Greenphire Partner to Deliver a First-of-its-Kind Patient Engagement Solution
FDA Approves Genentechís Actemra (Tocilizumab) for the Treatment of CAR T Cell-Induced Cytokine Release Syndrome
Greenphire Named to Inc. 5000 for Fifth Consecutive Year
Five Community Health Centers Honored for Innovative Approaches to Medication Therapy Management
FDA Grants Priority Review for Genentechís Gazyva in Previously Untreated Follicular Lymphoma
ProSci Incorporates Flow Cytometry Screening to Custom Monoclonal Antibody Service
FDA Grants Priority Review to Genentech's Emicizumab for Hemophilia A with Inhibitors
BD Expands Suite of Blood Culture Offerings with New BD BACTECô Standard Aerobic & Standard Anaerobic Plastic Bottles

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
 
NewswireToday Celebrates 10 Years in Business
Find business coaching, life coaching, executive coaching and corporate coaching, best selling coaching books, ...



PREMIUM Members


Visit  RightITnow Ltd

Visit  JobsWare.com

Visit  NAKIVO, Inc.







 
  ©2017 PRZOOM ó Limelon Advertising, Co.
Home | About PRZOOM | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneur newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today